Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Open Access
- 14 August 2020
- Vol. 12 (8), 2274
- https://doi.org/10.3390/cancers12082274
Abstract
T-cell exhaustion is a phenomenon that represents the dysfunctional state of T cells in chronic infections and cancer and is closely associated with poor prognosis in many cancers. The endogenous T-cell immunity and genetically edited cell therapies (CAR-T) failed to prevent tumor immune evasion. The effector T-cell activity is perturbed by an imbalance between inhibitory and stimulatory signals causing a reprogramming in metabolism and the high levels of multiple inhibitory receptors like programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and Lymphocyte-activation gene 3 (Lag-3). Despite the efforts to neutralize inhibitory receptors by a single agent or combinatorial immune checkpoint inhibitors to boost effector function, PDAC remains unresponsive to these therapies, suggesting that multiple molecular mechanisms play a role in stimulating the exhaustion state of tumor-infiltrating T cells. Recent studies utilizing transcriptomics, mass cytometry, and epigenomics revealed a critical role of Thymocyte selection-associated high mobility group box protein (TOX) genes and TOX-associated pathways, driving T-cell exhaustion in chronic infection and cancer. Here, we will review recently defined molecular, genetic, and cellular factors that drive T-cell exhaustion in PDAC. We will also discuss the effects of available immune checkpoint inhibitors and the latest clinical trials targeting various molecular factors mediating T-cell exhaustion in PDAC.Keywords
This publication has 206 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- TH17 cells in tumour immunity and immunotherapyNature Reviews Immunology, 2010
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active TargetJournal of the American College of Surgeons, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathwayThe EMBO Journal, 2006
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002